JUNS

Jupiter Neurosciences, Inc. Developing therapies for Parkinson’s and Longevity & Healthspan

[JUNS @JupiterOrphan]

My mother died after 12 years of battling Alzheimer’s and that’s why we now have launched https://t.co/NdBpS2jixA. Key ingredient backed by NIA research and now entering Phase II in Patkinson’s. MCI/early AD will be the next trial. If you are taking supplements for Alzheimer’s you must check Nugevia for your own sake

[JUNS @JupiterOrphan]

https://t.co/0EMsN2OKW9

[JUNS @JupiterOrphan]

$50B+ Longevity Opportunity: Jupiter Neurosciences CEO Christer Rosen & President Alison Silva, Live at Nasdaq https://t.co/0EMsN2OKW9

[JUNS @JupiterOrphan]

Great day in NYC!! #JUNS #Nugevia

[Jupiter Neurosciences, Inc. @jupiterneuro]

Where #biohacking meets #longevity: Jean Fallacara (@cyborggainz), entrepreneur & neuroscientist, joins Nugevia™ as our third brand ambassador. We’re turning clinical breakthroughs into everyday wellness wins.
Learn more: https://t.co/cNgyOShPQX

$JUNS

[Jupiter Neurosciences, Inc. @jupiterneuro]

From court to everyday life — longevity, resilience, and peak performance matter🏀 That’s why NBA legend & Hall of Famer inductee Chris Webber @realchriswebber is joining us as Nugevia’s second Brand Ambassador. Learn more 👉 https://t.co/un3uLuAKLa
$JUNS

[Jupiter Neurosciences, Inc. @jupiterneuro]

Golf is a game of resilience—and Hall of Fame legend Annika Sörenstam @ANNIKA59 knows it best. As the first Nugevia™ Brand Ambassador, her story shows how science-backed supplements put neuro health at the core of longevity. Learn more: https://t.co/vYmD5mWDJs $JUNS

[Jupiter Neurosciences, Inc. @jupiterneuro]

Pre-orders are live at https://t.co/ZjMiqIkT5X. Built on our patented JOTROL™ resveratrol platform (9x bioavailability in Phase I clinical trials), Nugevia™ brings pharma-grade science to longevity.
🔗Learn more: https://t.co/EvjChUzirQ
$JUNS

[JUNS @JupiterOrphan]

You need to check this short video!!!!!
https://t.co/xJlWeEbTKs

[JUNS @JupiterOrphan]

We are rewriting the script on Biotech

https://t.co/n3ycxcoK99

[JUNS @JupiterOrphan]

https://t.co/Mz4XDxEtcH

[RedChip @RedChip]

🌟 Jupiter Neurosciences $JUNS: Entering the $8 Trillion Longevity Market with Nugevia™ GLO

Jupiter Neurosciences unveiled Nugevia™ GLO, a premium “beauty-from-within” supplement backed by patented pharmaceutical science. GLO combines $JUNS' JOTROL™ resveratrol technology, proven to deliver 9x greater bioavailability, with NovaSOL® Astaxanthin for superior skin vitality, hydration, and cellular protection.

💡 Why This Matters for Investors:
✅ Strategic Market Expansion: First consumer product targeting the fast-growing longevity and wellness sector.
✅ High-Margin Revenue: Premium pricing and broad demographic appeal offer a robust parallel growth engine.
✅ Capital Efficiency: GLO revenues expected to support CNS clinical programs and enhance shareholder value.

📄 Learn more: https://t.co/jSWW5K091d

@JupiterOrphan $JUNS $PACB $VYGR $PFE $MRK #LongevityMarket #SkinHealth #PharmaInnovation #SmallCapStocks #Investing #Wellness

[RedChip @RedChip]

🎥 Jupiter Neurosciences $JUNS: Watch the 30-Second Snapshot Investors Can’t Miss

$JUNS is redefining treatment for CNS disorders and rare diseases through its breakthrough resveratrol-based therapy, JOTROL™, which delivers 9x greater bioavailability than traditional formulations. Backed by leading institutions like Harvard and $1.76M in NIH funding, the company is advancing toward multiple Phase 2 trials in 2025.

💡 Why This Matters to Investors:
🌐 Addressing $50B+ in combined market opportunities across Alzheimer’s, Parkinson’s, and rare diseases.
🧪 Clinical and commercial strategy: Prescription therapies and near-term nutraceutical revenue stream.
🔬 Validated science, global scalability, and a clear roadmap to value creation.

▶️ Watch the 30-sec Company Overview Now
🔗 https://t.co/GgdsVN5yS8

@JupiterOrphan $JUNS $PACB $VYGR $PFE $MRK #JUNS #BiotechInvesting #Neurodegeneration #RareDiseases #ClinicalTrials #PharmaInnovation #InvestorUpdate #LongevityMarkets

[JUNS @JupiterOrphan]

https://t.co/jNNjBivbe2

[JUNS @JupiterOrphan]

We are taking the next steps in what might be the next generation of Biotech models #Parkinsonsdisease #mitochondria #Longevity #Healthspan #Beautyfromwithin https://t.co/lyY7WK0Yyh

[JUNS @JupiterOrphan]

Jupiter Neurosciences, Inc. Announces Journal of Alzheimer's Disease Publication Highlighting use of JOTROL™ https://t.co/sNrsc2QaPT

[JUNS @JupiterOrphan]

Jupiter Orphan Therapeutics, Inc. Announces New Corporate Name, Jupiter Neurosciences, Inc. https://t.co/rKg23coSmu

[JUNS @JupiterOrphan]

@RudyTanzi @Forbes Congrats!!! Well deserved!!!

[JUNS @JupiterOrphan]

@davidasinclair You need JOTROL!!!